Acquired resistance to selective FGFR inhibitors in FGFR-altered cholangiocarcinoma

被引：0
|
作者：
Goyal, L. [1 ]
Baiev, I. [1 ]
Zhang, K. [2 ]
Dalgai, S. [3 ]
Shroff, R. T. [4 ]
Kelley, R. K. [2 ]
Uboha, N. [5 ]
机构：
[1] Massachusetts Gen Hosp, Gastrointestinal Oncol, Boston, MA 02114 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Gastrointestinal Oncol, San Francisco, CA 94143 USA
[3] Univ Arizona, Dept Med, Coll Med, Tucson, AZ USA
[4] Univ Arizona, Div Hematol & Oncol, Coll Med, Tucson, AZ USA
[5] Univ Wisconsin, Div Hematol & Oncol, Carbone Canc Ctr, Madison, WI USA
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
49
引用
收藏
页码：S21 / S22
页数：2
相关论文
共 50 条
  • [1] FGFR-altered cholangiocarcinoma
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (02): : 81 - 81
  • [2] BGJ398 for FGFR-altered advanced cholangiocarcinoma
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2018, 19 (01): : E16 - E16
  • [3] Unveiling targets and resistance in FGFR-altered cancers
    Westphalen, C. B.
    ANNALS OF ONCOLOGY, 2025, 36 (04) : 359 - 360
  • [4] Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
    Wu, Qibiao
    Ellis, Haley
    Siravegna, Giulia
    Michel, Alexa G.
    Norden, Bryanna L.
    de la Cruz, Ferran Fece
    Balasooriya, Eranga Roshan
    Zhen, Yuanli
    Silveira, Vanessa S.
    Che, Jianwe
    Corcoran, Ryan B.
    Bardeesy, Nabeel
    CLINICAL CANCER RESEARCH, 2024, 30 (01) : 198 - 208
  • [5] A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma
    Daniel H. Ahn
    Pedro Luiz Serrano Uson Junior
    Peter Masci
    Heidi Kosiorek
    Thorvardur R. Halfdanarson
    Kabir Mody
    Hani Babiker
    Thomas DeLeon
    Mohamad Bassam Sonbol
    Gregory Gores
    Rory Smoot
    Tanios Bekaii-Saab
    Amit Mahipal
    Aaron Mansfield
    Nguyen H. Tran
    Joleen M. Hubbard
    Mitesh J. Borad
    Investigational New Drugs, 2022, 40 : 134 - 141
  • [6] Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
    Benjamin, David J.
    Mar, Nataliya
    Rezazadeh Kalebasty, Arash
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [7] A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma
    Ahn, Daniel H.
    Uson Junior, Pedro Luiz Serrano
    Masci, Peter
    Kosiorek, Heidi
    Halfdanarson, Thorvardur R.
    Mody, Kabir
    Babiker, Hani
    DeLeon, Thomas
    Sonbol, Mohamad Bassam
    Gores, Gregory
    Smoot, Rory
    Bekaii-Saab, Tanios
    Mahipal, Amit
    Mansfield, Aaron
    Tran, Nguyen H.
    Hubbard, Joleen M.
    Borad, Mitesh J.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 134 - 141
  • [8] Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
    Benjamin, David J.
    Mar, Nataliya
    Kalebasty, Arash Rezazadeh
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [9] Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma
    Krook, Melanie A.
    Lenyo, Alexandria M.
    Wilberding, Maxwell J.
    Barker, Hannah D.
    Dantuono, Mikayla
    Chen, Hui-Zi
    Reeser, Julie W.
    Wing, Michele R.
    Miya, Jharna
    Samorodnitsky, Eric
    Smith, Amy M.
    Dao, Thuy
    Martin, Dorrelyn M.
    Dittmar, Kristin
    Ciombor, Kristen K.
    Hays, John L.
    Freud, Aharon G.
    Roychowdhury, Sameek
    CANCER RESEARCH, 2019, 79 (13)
  • [10] Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
    Krook, Melanie A.
    Lenyo, Alexandria
    Wilberding, Max
    Barker, Hannah
    Dantuono, Mikayla
    Bailey, Kelly M.
    Chen, Hui-Zi
    Reeser, Julie W.
    Wing, Michele R.
    Miya, Jharna
    Samorodnitsky, Eric
    Smith, Amy M.
    Thuy Dao
    Martin, Dorrelyn M.
    Ciombor, Kristen K.
    Hays, John
    Freud, Aharon G.
    Roychowdhury, Sameek
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (03) : 847 - 857
12345